Summary
TEVA Chart
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously announced tender offers (the “Offers”) to purchase for cash the outstanding notes issued by finance subsidiaries of Teva and guaranteed by Teva of the series described in the table below (the “Notes”) upon the terms of, and subject to the conditions as set out in, the Offer to Purchase, dated May 19, 2025 (the “Offer to Purchase”). Capitalized terms used in this announcement but not otherwise defined shall have the meanings given to them in the Offer to Purchase.
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a study of treatment patterns among patients with tardive dyskinesia (TD) residing in long-term care (LTC) facilities, highlighting a critical gap in TD diagnosis and treatment.
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with T
PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of real-world clinical outcomes, treatment patterns and healthcare resource utilization (HCRU) data evaluating UZEDY® (risperidone), an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, versus second-generation daily oral options. In the studies, patients receiving UZEDY had lower rates of and longer time to relapse as well as better treatment adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits, shorter hospital length of stay and lower all-cause HCRU. Additionally, Phase 3 SOLARIS data show no incidence of post-injection delirium/sedation syndrome (PDSS) to date in participants taking TEV-'749, a once-monthly, long-acting injectable (LAI) subcutaneous formulation of olanzapine. The systemic safety profile was consistent with approved olanzapine options. The data were presented at the 2025 Psych Congress Elevate Annual Meeting, taking place from May 28-31, 2025, in Las Vegas, Nevada.
Teva Pharmaceutical Industries Ltd. ADR Dividends
 TEVA 27 Nov 2017 Paid | Quarterly | $0.09 Per Share |
| TEVA 25 Aug 2017 Paid | Quarterly | $0.09 Per Share |
| TEVA 1 Jun 2017 Paid | Quarterly | $0.34 Per Share |
| TEVA 28 Feb 2017 Paid | Quarterly | $0.34 Per Share |
| TEVA 1 Dec 2016 Paid | Quarterly | $0.34 Per Share |
Teva Pharmaceutical Industries Ltd. ADR Earnings
| 6 May 2025 Date | | 0.46 Cons. EPS | 0.52 EPS |
| 29 Jan 2025 Date | | 0.7 Cons. EPS | 0.71 EPS |
| 6 Nov 2024 Date | | 0.65 Cons. EPS | 0.69 EPS |
| 31 Jul 2024 Date | | 0.55 Cons. EPS | 0.61 EPS |
| 8 May 2024 Date | | 0.51 Cons. EPS | 0.48 EPS |
| TEVA 27 Nov 2017 Paid | Quarterly | $0.09 Per Share |
| TEVA 25 Aug 2017 Paid | Quarterly | $0.09 Per Share |
| TEVA 1 Jun 2017 Paid | Quarterly | $0.34 Per Share |
| TEVA 28 Feb 2017 Paid | Quarterly | $0.34 Per Share |
| TEVA 1 Dec 2016 Paid | Quarterly | $0.34 Per Share |
| 6 May 2025 Date | | 0.46 Cons. EPS | 0.52 EPS |
| 29 Jan 2025 Date | | 0.7 Cons. EPS | 0.71 EPS |
| 6 Nov 2024 Date | | 0.65 Cons. EPS | 0.69 EPS |
| 31 Jul 2024 Date | | 0.55 Cons. EPS | 0.61 EPS |
| 8 May 2024 Date | | 0.51 Cons. EPS | 0.48 EPS |
Teva Pharmaceutical Industries Ltd. ADR (TEVA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Teva Pharmaceutical Industries Ltd. ADR ever had a stock split?
Teva Pharmaceutical Industries Ltd. ADR Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Richard D. Francis CEO | NYSE Exchange | 881624209 Cusip |
| IL Country | 37,000 Employees | 12 Dec 2017 Last Dividend | 1 Jul 2004 Last Split | - IPO Date |
Overview
Teva Pharmaceutical Industries Limited is a prominent global company with a focus on developing, manufacturing, marketing, and distributing a wide range of pharmaceutical products. Its operations span across North America, Europe, Israel, and other international markets. Teva's portfolio includes generic medicines, specialty medicines, and biopharmaceutical products, catering to various dosage forms and therapeutic areas. With a history dating back to 1901, the company has established itself as a leader in the pharmaceutical industry, headquartered in Tel Aviv, Israel. Teva is known for its contribution to central nervous system (CNS), respiratory, and oncology therapeutic areas, providing active pharmaceutical ingredients and contract manufacturing services, alongside operating an out-licensing platform for other pharmaceutical companies. Teva's commitment to healthcare and therapeutic advancements is evident through its collaboration agreements with MedinCell, Sanofi, Alvotech, and Biolojic Design Ltd., as well as a license agreement with MODAG GmbH.
Products and Services
BENDEKA and TREANDA injections: Used for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma, these injections underscore Teva's focus on oncology.
GRANIX, TRISENOX, LONQUEX, and TEVAGRASTIM/RATIOGRASTIM: These products exemplify Teva's commitment to providing supportive care in oncology, including treatments for neutropenia and arsenic trioxide for leukemia.
COPAXONE: This flagship product for the treatment of relapsing forms of multiple sclerosis highlights Teva's innovation in CNS therapies.
AJOVY: A treatment for the preventive care of migraine in adults, AJOVY is part of Teva's specialty medicine range aimed at improving quality of life for migraine sufferers.
AUSTEDO: Focused on neurodegenerative and movement disorders, AUSTEDO is used for treating conditions associated with Huntington's disease and tardive dyskinesia.
UZEDY: This antipsychotic is used for the treatment of schizophrenia, reflecting Teva's ongoing development in CNS health.
Respiratory Products: Teva offers a suite of respiratory products like ProAir RespiClick inhalation powder, QVAR for asthma, BRALTUS, CINQAIR/CINQAERO injection, DuoResp Spiromax, and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder, addressing a broad spectrum of respiratory conditions.
OTC Products: Teva's over-the-counter (OTC) offerings under brands such as SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA, cater to a variety of everyday health needs, from skincare to cold and flu relief.
In addition to its broad spectrum of pharmaceutical products, Teva Pharmaceutical Industries Limited also provides active pharmaceutical ingredients and contract manufacturing services, demonstrating its versatility and comprehensive approach to healthcare solutions.
Contact Information
